NASDAQ:TPST - Tempest Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $9.33
  • Forecasted Upside: -37.82 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$15.01
▼ -1.73 (-10.33%)

This chart shows the closing price for TPST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tempest Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TPST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TPST

Analyst Price Target is $9.33
▼ -37.82% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Tempest Therapeutics in the last 3 months. The average price target is $9.33, with a high forecast of $23.00 and a low forecast of $2.00. The average price target represents a -37.82% upside from the last price of $15.01.

This chart shows the closing price for TPST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Tempest Therapeutics. This rating has held steady since August 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/31/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/13/2021HC WainwrightInitiated CoverageBuyHigh
7/6/2021Piper SandlerInitiated CoverageOverweight$23.00High
1/6/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$5.00 ➝ $2.00N/A
1/6/2021LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralN/A
8/12/2020WedbushReiterated RatingHold$3.00Low
6/14/2020SVB LeerinkReiterated RatingOutperform$5.00Medium
6/14/2020Roth CapitalReiterated RatingBuy$6.00Medium
5/29/2020CitigroupInitiated CoverageBuy$6.00High
5/21/2020OppenheimerReiterated RatingHold$2.00High
4/19/2020OppenheimerDowngradeOutperform ➝ Market PerformMedium
4/7/2020Roth CapitalLower Price Target$35.00 ➝ $6.00Medium
4/6/2020OppenheimerDowngradeOutperform ➝ Market Perform$25.00 ➝ $2.00High
4/6/2020WedbushDowngradeOutperform ➝ Neutral$25.00 ➝ $4.00High
3/24/2020CitigroupLower Price TargetBuy$23.00 ➝ $20.00Low
2/7/2020CitigroupInitiated CoverageBuy$23.00High
1/20/2020SVB LeerinkReiterated RatingOutperformMedium
1/10/2020Roth CapitalInitiated CoverageBuy$35.00High
9/16/2019Jefferies Financial GroupReiterated RatingBuy$22.00High
8/15/2019WedbushReiterated RatingBuy$24.00Low
8/13/2019OppenheimerLower Price TargetOutperform$26.00 ➝ $25.00Low
7/18/2019WedbushInitiated CoverageOutperform$24.00Low
7/16/2019CIBCInitiated CoverageOutperform ➝ Outperform$26.00Medium
7/16/2019OppenheimerInitiated CoverageOutperform$26.00 ➝ $26.00High
7/15/2019CitigroupInitiated CoverageOutperform$26.00High
3/13/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$22.00High
1/4/2019LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$29.00N/A
12/13/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$24.00N/A
(Data available from 7/25/2016 forward)
Tempest Therapeutics logo
Millendo Therapeutics, Inc. is a biopharmaceutical company, which engages in seeking distinct and transformative treatments where there is a significant unmet medical need. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI.
Read More

Today's Range

Now: $15.01
Low: $15.01
High: $16.60

50 Day Range

MA: $7.05
Low: $1.06
High: $24.19

52 Week Range

Now: $15.01
Low: $10.39
High: $41.55

Volume

151,036 shs

Average Volume

1,765,938 shs

Market Capitalization

$19.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.43

Frequently Asked Questions

What sell-side analysts currently cover shares of Tempest Therapeutics?

The following sell-side analysts have issued reports on Tempest Therapeutics in the last year: HC Wainwright, LADENBURG THALM/SH SH, Piper Sandler, SVB Leerink LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for TPST.

What is the current price target for Tempest Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Tempest Therapeutics in the last year. Their average twelve-month price target is $9.33, suggesting a possible downside of 37.8%. Piper Sandler has the highest price target set, predicting TPST will reach $23.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $2.00 for Tempest Therapeutics in the next year.
View the latest price targets for TPST.

What is the current consensus analyst rating for Tempest Therapeutics?

Tempest Therapeutics currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TPST, but not buy more shares or sell existing shares.
View the latest ratings for TPST.

What other companies compete with Tempest Therapeutics?

How do I contact Tempest Therapeutics' investor relations team?

Tempest Therapeutics' physical mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company's listed phone number is (734) 845-9000 and its investor relations email address is [email protected] The official website for Tempest Therapeutics is www.millendo.com.